Clinical Trials Directory

Trials / Unknown

UnknownNCT03153566

Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients

Comparison Between Tuberculin Vaccine and Cryotherapy in the Treatment of Genital Wart Patients

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
45 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
20 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Cutaneous and genital warts are common dermatological conditions caused by Human Papilloma Virus. Although it is a benign condition it causes disfigurement, has tendency to collect, can be transmitted to others, this makes adequate and timely treatment important, while many warts are resolve spontaneously over several years, most patients seek treatment because the warts are unsightly and often tender or painful.

Detailed description

Genital warts are highly contagious sexually transmitted diseases (STD) caused by infection of Human Papilloma Virus and, as the most common STD in developed countries, can currently be considered to be globally epidemic. It is estimated that the frequency of Human Papilloma Virus infection among women in the world ranges from 2% to 44%. The conventional modalities in treatment of warts include destructive therapies such as salicylic acid, trichloroacetic acid, cryotherapy, silver nitrate, phenol, cantharidin, surgical interventions and laser, antiproliferative agents such as bleomycin, vitamin D analogs, podophyllin, 5 fluorouracil and antiviral agents such as cidofovir and retinoids. There are different mechanisms have been proposed for the resolution of warts with skin test antigens such as mumps, candida, trichophyton both at the injected as well as distant sites. Tuberculin: Purified protein derivative or tuberculin stimulates the cell mediated immunity non specifically by activating T helper 1 cells, Natural Killer cells, and cytokine production an increase in interleukin-12 as a process in boosting the cell-mediated immunity contributes to the mechanism of action.

Conditions

Interventions

TypeNameDescription
BIOLOGICALtuberculininject the mother wart with .3 ml tuberculin vaccine every 2 weeks
DEVICEcryotherapy10 sec 1 cycle into all genital warts

Timeline

Start date
2017-06-01
Primary completion
2018-06-01
Completion
2018-12-01
First posted
2017-05-15
Last updated
2017-05-17

Source: ClinicalTrials.gov record NCT03153566. Inclusion in this directory is not an endorsement.

Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients (NCT03153566) · Clinical Trials Directory